// App-Quantinova.ai

: Gemcitabine-based neoadjuvant treatment in borderline resectable pancreatic ductal adenocarcinoma: a systematic review and meta-analysis of individual patient data

Researchers

Presenter

  • F. Giovinazzo

Principal Investigators

  • F. Soggiu

  • C.M. Kang

  • M.M. Zalupski

  • S. Yentz

  • S. Helton

  • J.B. Rose

  • C. Takishita

  • Y. Nagakawa

  • M. Abu-Hilal

Medical Centers

  • Department of Surgery, Southampton University Hospital NHS Foundation Trust, United Kingdom

  • HPB, Royal Free Hospital, United Kingdom

  • Surgery, Chungbuk National University College of Medicine, Republic of Korea

  • University of Michigan, Michigan, United States

  • General, Thoracic and Vascular Surgery, Virginia Mason Medical Center, Seattle, Washington, United States

  • Section of Surgical Oncology, University of Alabama, United States

  • Department of Gastrointestinal and Pediatric Surgery, Tokyo Medical University, Tokyo, Japan

Locations

  • United Kingdom

  • Republic of South Korea

  • United States

  • Japan

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Pancreas ductal adenocarcinoma

  • Microphthalmia, syndromic, 9

Biomarkers

  • N/A

Drug/Treatment

  • Gemcitabine

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved